+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Non-Cystic Fibrosis Bronchiectasis (NCFB) Market Insight, Epidemiology and Market Forecast - 2028

  • ID: 4871922
  • Drug Pipelines
  • October 2019
  • Region: Global
  • 120 Pages +
  • DelveInsight
1 of 2
“Non-Cystic Fibrosis Bronchiectasis (NCFB) - Market Insights, Epidemiology and Market Forecast - 2028” report provides the detailed overview of the disease and in depth understanding of historical and forecasted epidemiology. It highlights the existing treatment patterns, potential upcoming drugs and also identifies best of the market opportunities by providing the current and forecasted market revenue, sales trends, and drug uptake during the study period from 2017 - 2028.

Markets Covered
  • United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan
Study Period: 2017 - 2028

Non-Cystic Fibrosis Bronchiectasis (NCFB) Understanding and Treatment Algorithm

The report provides the in depth analysis of the disease overview by providing details such as disease definition, classification, symptoms, etiology, pathophysiology and diagnostic trends. The comprehensive details about treatment algorithms and treatment guidelines for Non-Cystic Fibrosis Bronchiectasis (NCFB) in the US, Europe, and Japan are also provided in the report.

Non-Cystic Fibrosis Bronchiectasis (NCFB) Epidemiology

This section provide the insights about historical and current patient pool and forecasted trend for 7 major markets. It takes in to account the analysis of numerous studies, survey reports as well as KOL's views which helps to recognize the factors behind the current and forecasted trends, diagnosed and treatable patient pool along with assumptions undertaken.

Non-Cystic Fibrosis Bronchiectasis (NCFB) Product Profiles & Analysis
This part of the Non-Cystic Fibrosis Bronchiectasis (NCFB) report encloses the detailed analysis of marketed drugs and Phase III and late Phase II pipeline drugs. It provides the key cross competition which evaluates the drugs on several parameters including, safety & efficacy results, mechanism of action, route, launch dates and designations. This section also covers the market intelligence and tracking of latest happenings, agreements and collaborations, approvals, patent details and other major breakthroughs.

Non-Cystic Fibrosis Bronchiectasis (NCFB) Market Outlook

The Non-Cystic Fibrosis Bronchiectasis (NCFB) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. This segment analyses the market trend of each marketed drug and late - stage pipeline drugs. This is done by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders . The calculated market data is presented with relevant tables and graphs to give a clear view of the market at first sight.

Non-Cystic Fibrosis Bronchiectasis (NCFB) Market Share by Therapies
This section focusses on the rate of uptake of the potential drugs recently launched or will be launched in the market during the study period from 2017 - 2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug. This information also helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It provides the comparison of the drugs on the basis of market share and size. This analysis helps in investigating factors important in market uptake and in making financial as well as regulatory decisions.

Non-Cystic Fibrosis Bronchiectasis (NCFB) Report Insights
  • Patient Population in Non-Cystic Fibrosis Bronchiectasis (NCFB)
  • Therapeutic Approaches in Non-Cystic Fibrosis Bronchiectasis (NCFB)
  • Non-Cystic Fibrosis Bronchiectasis (NCFB) Pipeline Analysis
  • Non-Cystic Fibrosis Bronchiectasis (NCFB) Market Size and Trends
  • Non-Cystic Fibrosis Bronchiectasis (NCFB) Market Opportunities
  • Impact of upcoming Therapies in Non-Cystic Fibrosis Bronchiectasis (NCFB)
Non-Cystic Fibrosis Bronchiectasis (NCFB) Report Key Strengths
  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition
Non-Cystic Fibrosis Bronchiectasis (NCFB) Report Assessment
  • Current Treatment Practices in Non-Cystic Fibrosis Bronchiectasis (NCFB)
  • Unmet Needs in Non-Cystic Fibrosis Bronchiectasis (NCFB)
  • Detailed Non-Cystic Fibrosis Bronchiectasis (NCFB) Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
Key Benefits
  • This report will help to develop Business Strategies by understanding the trends shaping and driving the Non-Cystic Fibrosis Bronchiectasis (NCFB) market
  • Organize sales and marketing efforts by identifying the best opportunities for Non-Cystic Fibrosis Bronchiectasis (NCFB) market
  • To understand the future market competition in the Non-Cystic Fibrosis Bronchiectasis (NCFB) market.
Note: Product cover images may vary from those shown
2 of 2

1. Report Introduction

2. Non-Cystic Fibrosis Bronchiectasis (NCFB) Market Overview at a Glance
2.1. Market Share Distribution of Non-Cystic Fibrosis Bronchiectasis (NCFB) in 2018
2.2. Market Share Distribution of Non-Cystic Fibrosis Bronchiectasis (NCFB) in 2028

3. Disease Background and Overview: Non-Cystic Fibrosis Bronchiectasis (NCFB)
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment

4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Non-Cystic Fibrosis Bronchiectasis (NCFB) in 7MM
4.3. Total Prevalent Patient Population of Non-Cystic Fibrosis Bronchiectasis (NCFB) in 7MM - By Countries

5. Epidemiology of Non-Cystic Fibrosis Bronchiectasis (NCFB) by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB)
5.1.3. Sub-Type Specific cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) *
5.1.4. Sex- Specific Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) *
5.1.5. Diagnosed Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB)
5.1.6. Treatable Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB)
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB)
5.4.3. Sub-Type Specific cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) *
5.4.4. Sex- Specific Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) *
5.4.5. Diagnosed Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB)
5.4.6. Treatable Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB)
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB)
5.5.3. Sub-Type Specific cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) *
5.5.4. Sex- Specific Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) *
5.5.5. Diagnosed Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB)
5.5.6. Treatable Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB)
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB)
5.6.3. Sub-Type Specific cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) *
5.6.4. Sex- Specific Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) *
5.6.5. Diagnosed Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB)
5.6.6. Treatable Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB)
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB)
5.7.3. Sub-Type Specific cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) *
5.7.4. Sex- Specific Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) *
5.7.5. Diagnosed Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB)
5.7.6. Treatable Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB)
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB)
5.8.3. Sub-Type Specific cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) *
5.8.4. Sex- Specific Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) *
5.8.5. Diagnosed Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB)
5.8.6. Treatable Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB)
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB)
5.9.3. Sub-Type Specific cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) *
5.9.4. Sex- Specific Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB) *
5.9.5. Diagnosed Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB)
5.9.6. Treatable Cases of the Non-Cystic Fibrosis Bronchiectasis (NCFB)

6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines

7. Unmet Needs of the Non-Cystic Fibrosis Bronchiectasis (NCFB)

8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile

9. Pipeline Therapies - At a glance

10. Key Cross Competition

11. Emerging Therapies for Non-Cystic Fibrosis Bronchiectasis (NCFB)
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages
11.2.5. Pipeline Development Activities
11.2.6. Product Profile

12. Non-Cystic Fibrosis Bronchiectasis (NCFB) : 7MM Market Analysis
12.1. 7MM Market Size of Non-Cystic Fibrosis Bronchiectasis (NCFB)
12.2. 7MM Percentage Share of drugs marketed for Non-Cystic Fibrosis Bronchiectasis (NCFB)
12.3. 7MM Market Sales of Non-Cystic Fibrosis Bronchiectasis (NCFB) by Products

13. Non-Cystic Fibrosis Bronchiectasis (NCFB) : Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Non-Cystic Fibrosis Bronchiectasis (NCFB) in United States
13.1.2. Percentage Share of drugs marketed for Non-Cystic Fibrosis Bronchiectasis (NCFB) in United States
13.1.3. Market Sales of Non-Cystic Fibrosis Bronchiectasis (NCFB) by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Non-Cystic Fibrosis Bronchiectasis (NCFB) in Germany
13.2.1.2. Percentage Share of drugs marketed for Non-Cystic Fibrosis Bronchiectasis (NCFB) in Germany
13.2.1.3. Market Sales of Non-Cystic Fibrosis Bronchiectasis (NCFB) by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Non-Cystic Fibrosis Bronchiectasis (NCFB) in France
13.2.2.2. Percentage Share of drugs marketed for Non-Cystic Fibrosis Bronchiectasis (NCFB) in France
13.2.2.3. Market Sales of Non-Cystic Fibrosis Bronchiectasis (NCFB) by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Non-Cystic Fibrosis Bronchiectasis (NCFB) in Italy
13.2.3.2. Percentage Share of drugs marketed for Non-Cystic Fibrosis Bronchiectasis (NCFB) in Italy
13.2.3.3. Market Sales of Non-Cystic Fibrosis Bronchiectasis (NCFB) by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Non-Cystic Fibrosis Bronchiectasis (NCFB) in Spain
13.2.4.2. Percentage Share of drugs marketed for Non-Cystic Fibrosis Bronchiectasis (NCFB) in Spain
13.2.4.3. Market Sales of Non-Cystic Fibrosis Bronchiectasis (NCFB) by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Non-Cystic Fibrosis Bronchiectasis (NCFB) in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Non-Cystic Fibrosis Bronchiectasis (NCFB) in United Kingdom
13.2.5.3. Market Sales of Non-Cystic Fibrosis Bronchiectasis (NCFB) by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Non-Cystic Fibrosis Bronchiectasis (NCFB) in Japan
13.3.2. Percentage Share of drugs marketed for Non-Cystic Fibrosis Bronchiectasis (NCFB) in Japan
13.3.3. Market Sales of Non-Cystic Fibrosis Bronchiectasis (NCFB) by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market

14. Market Drivers

15. Market Barriers

16. Appendix

17. Report Methodology
17.1. Sources

18. Publisher Capabilities

19. Disclaimer

20. About the Publisher

*Indication Specific

Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll